Completed PHASE3 INTERVENTIONAL NCT00215865

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

HRN 003PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

Sponsor: Hepatitis Resource Network

Conditions Chronic Hepatitis C Virus Infection

Interventions PEGIntron plus ribavirin

Updated 4 times since 2017 Last updated: Sep 20, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Hepatitis C Virus Infection and is currently completed. Hepatitis Resource Network leads this study, which shows 4 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hepatitis Resource Network
Hoffmann-La Roche

Data source: Hepatitis Resource Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States